Lung cancer Posts - Page 3 of 52 on Medivizor

Evaluating the effectiveness and safety of sugemalimab plus platinum-based chemotherapy for first-line treatment of metastatic squamous and non-squamous non-small cell lung cancer.

Posted by Medivizor on May 8, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of sugemalimab (Cejemly) in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic squamous (Sq) and non-squamous (non-Sq) non-small cell lung cancer (NSCLC). The data showed that sugemalimab plus platinum-based chemotherapy...

Evaluating the effectiveness and feasibility of patient-reported outcome-based symptom management versus usual care in patients after lung cancer surgery.

Posted by Medivizor on Apr 10, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and feasibility of patient-reported outcome (PRO)-based symptom management versus usual care in patients after lung cancer surgery. The data showed that PRO-based symptom management after lung cancer surgery showed lower symptom burden and fewer complications than usual care for up to 4 weeks after...

Vacations for Adult Cancer Patients: Update

Posted by Peigi Chace on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update. Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Evaluating the effectiveness of immunotherapy in advanced lung cancer with and without brain metastases.

Posted by Medivizor on Feb 27, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of immunotherapy in advanced lung cancer (LC) patients with and without brain metastases (BMs). The data showed that immunotherapy significantly improved overall survival in LC patients with and without BMs. Some background In 20-40% of patients with advanced LC, the cancer spreads from the lung to...

Which sequence of treatment should be given first – local or systemic treatment for patients with non-small cell lung cancer and brain metastases?

Posted by Medivizor on Feb 13, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated which sequence of treatment should be given first, local or systemic (whole-body) treatment for patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs). The data showed that systemic treatment followed by local treatment was associated with longer survival for patients with NSCLC and BM. Some...

Is chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?

Posted by Medivizor on Feb 7, 2022 in Lung cancer | 0 comments

In a nutshell The study aimed to investigate the effectiveness and safety of atezolizumab (Tecentriq) versus best supportive care after chemotherapy in patients with resected early-stage non-small-cell lung cancer (NSCLC). The study showed atezolizumab is effective and has better outcomes than best supportive in these...

Can osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?

Posted by Medivizor on Jan 30, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of osimertinib (Tagrisso) as first-line therapy for older patients above 75 years with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). The data showed that osimertinib as first-line therapy is effective in these patients. However, osimertinib was...

Evaluating the effectiveness and safety of combining proton plus carbon-ion radiotherapy with chemotherapy given at the same time in patients with limited-stage small-cell lung cancer.

Posted by Medivizor on Jan 23, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of combining proton radiotherapy (PRT) plus carbon-ion radiotherapy (CIRT) with chemotherapy (CT) given at the same time in patients with limited-stage (LS) small cell lung cancer (SCLC). The data showed that PRT plus CIRT with CT given at the same time was effective with manageable side...

Evaluating the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer after surgery.

Posted by Medivizor on Jan 20, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) after surgery. The data showed that early recurrence after surgery was associated with poor survival outcomes in patients with stage IIIA-N2 NSCLC. Smoking history, large tumor size, increased lymph node ratio, and...

Comparing the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged NSCLC.

Posted by Medivizor on Jan 16, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC). The data showed that alectinib (Alecensa) and lorlatinib (Lorbrena) were the most effective and safest first-line treatment options for these patients. Some background...

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Posted by Medivizor on Dec 31, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small-cell lung cancer (NSCLC). The data showed that immunotherapies plus chemotherapy combination was the best treatment for improving overall survival whereas, immunotherapy plus anti-angiogenic therapy plus chemotherapy...

Evaluating the effectiveness and safety outcomes of durvalumab maintenance after chemoradiotherapy for unresectable stage 3 non-small-cell lung cancer.

Posted by Medivizor on Nov 28, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of durvalumab (Imfinzi) maintenance after chemoradiotherapy (CRT) in real-world patients with unresectable stage 3 non-small-cell lung cancer (NSCLC). The data showed that durvalumab maintenance after CRT was safe and showed good short-term survival outcomes in these...

Lung cancer Posts on Medivizor

Evaluating the effectiveness and safety of sugemalimab plus platinum-based chemotherapy for first-line treatment of metastatic squamous and non-squamous non-small cell lung cancer.

Evaluating the effectiveness and feasibility of patient-reported outcome-based symptom management versus usual care in patients after lung cancer surgery.

Vacations for Adult Cancer Patients: Update

Evaluating the effectiveness of immunotherapy in advanced lung cancer with and without brain metastases.

Which sequence of treatment should be given first – local or systemic treatment for patients with non-small cell lung cancer and brain metastases?

Is chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?

Can osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?

Evaluating the effectiveness and safety of combining proton plus carbon-ion radiotherapy with chemotherapy given at the same time in patients with limited-stage small-cell lung cancer.

Evaluating the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer after surgery.

Comparing the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged NSCLC.

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Evaluating the effectiveness and safety outcomes of durvalumab maintenance after chemoradiotherapy for unresectable stage 3 non-small-cell lung cancer.

Categories

Recent Posts

Archives

Lung cancer Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email